Biovest has developed a patient-specific, cancer vaccine, BiovaxID®, with three clinical trials completed.
Editor’s Note May 22, 2012
This week, OneMedRadio brings you two management interviews. Iconic Data, CEO David LaBorde discusses their lead product SwiftPayMD and why it is changing the face of patient billing. Opexa CEO, Neil Warma […]
“Rockstar of Science”, Eric Topol M.D. Talks The Creative Destruction of Medicine
Author of “The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Healthcare”, Dr. Eric Topol sits down with OneMedRadio to discuss the ideas and inspiration behind the book.
CIN Special Report: Part II, Treatments Ready to Eradicate Pre-Cervical Cancer
Part II of the report identifies several disruptive technologies that may overcome the challenges of mainstream treatments.
Editor’s Note May 1, 2012
This week, OneMedPlace brings you a special report on CIN. In response to some recent successes by several companies operating in the cervical cancer space, we are issuing a two-part special report […]
Dr. Shi of EdgeTech Law: Genome Sequencing Could Soon Enter Mainstream
In Part III of our interview with Dr. Qin Shi of Edgetech Law we visit the concept of human genome sequencing as a mainstream commodity.
Dr. Shi of EdgeTech Law: Emerging Opportunities in Life Sciences, Abroad
In Part II of our special interview series, Dr. Qin Shi of Edgetech Law discusses the emerging areas of significant unmet need in life science, and what investment opportunities may arise.
Biovest CEO and Sr. Vice President Discuss Global Marketing of BiovaxID
Biovest International, Inc. (OTCQB: BVTI) announced that Biovest is seeking marketing approval in Canada for BiovaxID®, its personalized cancer vaccine for the treatment of follicular non-Hodgkin’s lymphoma.
